Results 31 to 40 of about 73,607 (303)

JAK2 inhibitors

open access: yesMedicina Clínica (English Edition), 2016
Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms.
Juan Carlos, Hernández Boluda   +2 more
openaire   +5 more sources

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia [PDF]

open access: yes, 2017
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening for JAK2 mutations and translocations, analyzed the clinical outcome and ...
Marco J. Koudijs   +41 more
core   +1 more source

Blood cell activation as an indicator of prothrombogenesis in polycythemia vera: Case control study

open access: yesIraqi Journal of Hematology, 2019
BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative stem cell disease usually combined with JAK2 mutation. Active JAK2 mutation directly promote platelets and granulocytes activation and indirectly initiate endothelial activation.
Ibrahim A Mahmood   +2 more
doaj   +1 more source

Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review

open access: yesHematology/Oncology and Stem Cell Therapy, 2021
Primary myelofibrosis (PMF) is a subtype of BCR-ABL1 negative myeloproliferative neoplasm. Its characteristic features include clonal myeloproliferation, dysregulation of kinase signaling pathway, abnormal release of cytokines leading to fibrosis in the ...
Farhan Khalid   +4 more
doaj   +1 more source

A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs

open access: yesMolecular & Cellular Oncology, 2021
While Janus-kinase (JAK)-inhibitors effectively reduce the inflammatory phenotype of myeloproliferative neoplasms (MPN), they do not affect disease burden or presence of the mutated clone to a major extent. Here, we show how Janus-kinase 2 (JAK2)-mutated
Tina M. Schnoeder   +2 more
doaj   +1 more source

Table_1_Chronic Stress Activates PlexinA1/VEGFR2-JAK2-STAT3 in Vascular Endothelial Cells to Promote Angiogenesis.docx

open access: yes, 2021
It is known that chronic stress modulates multiple processes in a complex microenvironment, such as angiogenesis and immune function. However, the role of chronic stress inducing tumor angiogenesis and how it contributes to tumor progression are not ...
YanJie Lu (11276148)   +11 more
core   +1 more source

Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways [PDF]

open access: yesJournal of Biological Chemistry, 2008
Leptin controls body weight by activating the long form of the leptin receptor (LEPRb). Janus kinase 2 (JAK2) is associated with LEPRb and autophosphorylates in response to leptin. JAK2 also phosphorylates LEPRb, STAT3, and multiple other downstream molecules.
Lin, Jiang, Zhiqin, Li, Liangyou, Rui
openaire   +2 more sources

A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F)

open access: yesBiochemical Journal, 2010
JAK2 (Janus tyrosine kinase 2) is important for signalling through many cytokine receptors, and a gain-of-function JAK2 mutation in its pseudokinase domain, V617F, has been implicated in Philadelphia chromosome-negative myeloproliferative neoplasms. How this mutation hyperactivates JAK2 is poorly understood.
Lequn, Zhao   +3 more
openaire   +3 more sources

Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS

open access: yesHepatology, EarlyView., 2022
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou   +15 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

open access: yesHepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy